CBD Global Sciences Inc. (CBDNF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CBD Global Sciences Inc. (CBDNF) with AI Score 38/100 (Weak). CBD Global Sciences Inc. is involved in the cannabidiol (CBD) industry, focusing on farming, processing, and product manufacturing. The company offers a range of CBD products under various brand names. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026CBD Global Sciences Inc. (CBDNF) Healthcare & Pipeline Overview
CBD Global Sciences Inc. operates in the CBD market, engaging in farming, processing, and manufacturing CBD products. With brands like Aethics and CannaOil, the company caters to the growing demand for CBD-based solutions, facing competition and regulatory challenges in the evolving healthcare landscape.
Investment Thesis
Investing in CBD Global Sciences Inc. presents a high-risk, high-reward scenario. The company's negative P/E ratio of -0.20 and a significantly negative profit margin of -3469.4% indicate substantial financial challenges. A gross margin of 24.6% suggests some ability to generate profit from sales, but operational inefficiencies weigh heavily. The company's beta of 0.43 suggests lower volatility compared to the market. Growth depends on successful brand building, market penetration, and navigating regulatory hurdles. Key catalysts include potential changes in legislation that could broaden market access and increased consumer acceptance of CBD products. The company's ability to scale operations efficiently and achieve profitability will be critical for long-term success.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates the company's small size and potential for growth, but also higher risk.
- Negative P/E ratio of -0.20 reflects the company's current lack of profitability.
- Profit Margin of -3469.4% highlights significant operational challenges and high expenses relative to revenue.
- Gross Margin of 24.6% suggests potential for profitability if operational efficiencies are improved.
- Beta of 0.43 indicates lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Established brands: Aethics, CannaOil, and Strasburg Pharms.
- Vertically integrated operations.
- Proprietary formulations for CBD products.
Weaknesses
- Negative profitability and high operating expenses.
- Small market capitalization.
- Limited financial resources.
Catalysts
- Upcoming: Potential changes in legislation that could broaden market access for CBD products.
- Ongoing: Increasing consumer acceptance of CBD products for wellness and therapeutic applications.
- Ongoing: Expansion of distribution networks and partnerships with retailers.
- Upcoming: Potential for new product launches and innovative formulations.
- Ongoing: Research and development efforts to explore new therapeutic applications of CBD.
Risks
- Ongoing: Regulatory uncertainty and evolving legal landscape.
- Ongoing: Intense competition from established and emerging players.
- Potential: Fluctuations in raw material prices.
- Potential: Changing consumer preferences and market trends.
- Ongoing: Negative profitability and high operating expenses.
Growth Opportunities
- Expansion into new therapeutic areas represents a significant growth opportunity for CBD Global Sciences Inc. The company can invest in research and development to explore the potential of CBD in addressing specific health conditions, such as anxiety, pain management, and sleep disorders. Positive clinical trial results and subsequent regulatory approvals could lead to the development of novel CBD-based therapies, opening up new revenue streams and market segments. This expansion requires strategic partnerships with research institutions and healthcare providers.
- Geographic market expansion offers another avenue for growth. CBD Global Sciences Inc. can target new regions with favorable regulatory environments and growing consumer demand for CBD products. This expansion could involve establishing distribution networks, partnering with local retailers, or setting up operations in new countries. Careful market research and adaptation of product offerings to local preferences are essential for success. The global CBD market is projected to reach billions of dollars in the coming years, providing ample opportunities for growth.
- Development of innovative CBD product formulations can drive revenue growth. CBD Global Sciences Inc. can invest in research and development to create new and improved CBD products, such as enhanced edibles, topical creams, and transdermal patches. These innovative products can cater to specific consumer needs and preferences, differentiating the company from competitors. Collaborations with formulation experts and technology providers can accelerate the development process and ensure product quality and efficacy.
- Strategic partnerships with established healthcare companies can provide access to new markets and distribution channels. CBD Global Sciences Inc. can collaborate with pharmaceutical companies, nutraceutical manufacturers, or healthcare providers to co-develop and market CBD products. These partnerships can leverage the expertise and resources of established players, accelerating market penetration and building brand credibility. Due diligence and careful negotiation are essential to ensure mutually beneficial partnerships.
- Focus on sustainable and ethical sourcing of CBD can enhance brand reputation and attract environmentally conscious consumers. CBD Global Sciences Inc. can implement sustainable farming practices, obtain certifications for organic and fair-trade CBD, and promote its commitment to environmental stewardship. This focus on sustainability can differentiate the company from competitors and appeal to a growing segment of consumers who prioritize ethical and environmentally responsible products. Transparency and traceability throughout the supply chain are crucial for building trust with consumers.
Opportunities
- Expansion into new therapeutic areas.
- Geographic market expansion.
- Development of innovative CBD product formulations.
- Strategic partnerships with established healthcare companies.
Threats
- Regulatory uncertainty and evolving legal landscape.
- Intense competition from established and emerging players.
- Fluctuations in raw material prices.
- Changing consumer preferences and market trends.
Competitive Advantages
- Brand recognition through Aethics, CannaOil, and Strasburg Pharms brands.
- Vertically integrated operations, controlling aspects of the supply chain from cultivation to product distribution.
- Proprietary formulations and manufacturing processes for CBD products.
About CBDNF
CBD Global Sciences Inc., established in 2018 and headquartered in Lakewood, Colorado, operates within the cannabidiol (CBD) sector. The company's core business revolves around CBD farming, processing, and the manufacturing of a diverse range of CBD products. These products are marketed under several brand names, including Aethics, CannaOil, and Strasburg Pharms. The company cultivates biomass, extracts CBD oil, and formulates various CBD-infused products aimed at capitalizing on the increasing consumer interest in CBD for wellness and therapeutic applications. CBD Global Sciences seeks to establish a vertically integrated operation, controlling aspects of the supply chain from cultivation to product distribution. The company aims to differentiate itself through product quality, branding, and strategic partnerships within the evolving CBD market.
What They Do
- Farming of cannabidiol (CBD) biomass.
- Processing of CBD biomass to extract CBD oil.
- Manufacturing of CBD oil products.
- Marketing and sales of CBD products under the Aethics brand.
- Marketing and sales of CBD products under the CannaOil brand.
- Marketing and sales of CBD products under the Strasburg Pharms brand.
Business Model
- Cultivation of hemp to produce CBD-rich biomass.
- Extraction and refinement of CBD oil from the biomass.
- Formulation and manufacturing of various CBD products, including oils, tinctures, edibles, and topicals.
- Distribution and sale of CBD products through online channels, retail partnerships, and wholesale agreements.
Industry Context
CBD Global Sciences Inc. operates within the rapidly evolving CBD industry, a segment of the broader healthcare market. The industry is characterized by increasing consumer demand for CBD products, driven by perceived wellness benefits. However, the market is also highly competitive, with numerous players vying for market share. Regulatory uncertainty remains a significant challenge, as laws governing CBD production, distribution, and marketing vary widely across jurisdictions. The company faces competition from established players in the pharmaceutical, nutraceutical, and consumer goods industries, as well as smaller, specialized CBD companies. Success in this market requires effective branding, product innovation, and navigating the complex regulatory landscape.
Key Customers
- Consumers seeking CBD products for wellness and therapeutic purposes.
- Retailers and distributors of CBD products.
- Wholesale customers, including healthcare providers and other businesses.
Financials
Chart & Info
CBD Global Sciences Inc. (CBDNF) stock price: Price data unavailable
Latest News
No recent news available for CBDNF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBDNF.
Price Targets
Wall Street price target analysis for CBDNF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CBDNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Brad Wyatt
CEO
Brad Wyatt serves as the CEO of CBD Global Sciences Inc. His background includes experience in the cannabis and hemp industries, with a focus on business development and strategic partnerships. He has been involved in various aspects of the industry, from cultivation to product manufacturing and distribution. Wyatt's expertise lies in identifying market opportunities, building relationships with key stakeholders, and driving revenue growth. He has a track record of successfully launching new products and expanding market share in the competitive CBD market.
Track Record: Under Brad Wyatt's leadership, CBD Global Sciences Inc. has focused on expanding its product portfolio and distribution network. Key achievements include the development of new CBD product formulations and the establishment of partnerships with retailers and distributors. The company has also worked to enhance its brand recognition and build a loyal customer base. Wyatt has overseen the company's efforts to navigate the complex regulatory landscape and ensure compliance with all applicable laws and regulations.
CBDNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CBDNF may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, defunct businesses, or companies with questionable operations.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in CBDNF.
- Low trading volume and liquidity can lead to price volatility.
- Potential for fraud or manipulation is higher on the OTC market.
- OTC Other tier stocks are subject to less regulatory oversight.
- Difficulty in obtaining reliable information about the company's operations and financial condition.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the regulatory environment in which the company operates.
- Evaluate the company's liquidity and trading volume.
- Consult with a qualified financial advisor.
- The company has been in operation since 2018.
- The company has established brands: Aethics, CannaOil, and Strasburg Pharms.
- The company has a CEO in place.
CBD Global Sciences Inc. Stock: Key Questions Answered
What does CBD Global Sciences Inc. do?
CBD Global Sciences Inc. is a cannabidiol (CBD) company involved in the farming, processing, and manufacturing of CBD products. The company cultivates hemp, extracts CBD oil, and formulates various CBD-infused products, including oils, tinctures, edibles, and topicals. These products are marketed under the Aethics, CannaOil, and Strasburg Pharms brand names. The company distributes its products through online channels, retail partnerships, and wholesale agreements, targeting consumers seeking CBD for wellness and therapeutic purposes. The company aims to establish a vertically integrated operation, controlling aspects of the supply chain from cultivation to product distribution.
What do analysts say about CBDNF stock?
There is currently no available analyst coverage for CBDNF stock. The company's small market capitalization and OTC listing may limit analyst interest. Investors should conduct their own thorough research and due diligence before investing in CBDNF. Key valuation metrics, such as P/E ratio and profit margin, indicate significant financial challenges. Growth considerations include the company's ability to expand its product portfolio, penetrate new markets, and navigate the complex regulatory landscape. The stock's volatility and liquidity should also be carefully considered.
What are the main risks for CBDNF?
CBD Global Sciences Inc. faces several key risks, including regulatory uncertainty, intense competition, fluctuations in raw material prices, and changing consumer preferences. The evolving legal landscape surrounding CBD products creates uncertainty and potential compliance challenges. The company operates in a highly competitive market with numerous players vying for market share. Fluctuations in hemp prices can impact the company's profitability. Changes in consumer preferences and market trends can affect demand for the company's products. Additionally, the company's negative profitability and high operating expenses pose significant financial risks.
What are the key factors to evaluate for CBDNF?
CBD Global Sciences Inc. (CBDNF) currently holds an AI score of 38/100, indicating low score. Key strength: Established brands: Aethics, CannaOil, and Strasburg Pharms.. Primary risk to monitor: Ongoing: Regulatory uncertainty and evolving legal landscape.. This is not financial advice.
How frequently does CBDNF data refresh on this page?
CBDNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CBDNF's recent stock price performance?
Recent price movement in CBD Global Sciences Inc. (CBDNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established brands: Aethics, CannaOil, and Strasburg Pharms.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CBDNF overvalued or undervalued right now?
Determining whether CBD Global Sciences Inc. (CBDNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CBDNF?
Before investing in CBD Global Sciences Inc. (CBDNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data may be outdated or incomplete.